

No. 16-712

---

IN THE  
**Supreme Court of the United States**

---

OIL STATES ENERGY SERVICES, LLC,  
*Petitioner,*

*v.*

GREENE'S ENERGY GROUP, LLC, *et al.*,  
*Respondents.*

---

**On Writ of Certiorari  
to the United States Court of Appeals  
for the Federal Circuit**

---

**BRIEF OF  
AMERICA'S HEALTH INSURANCE PLANS  
AS AMICUS CURIAE  
IN SUPPORT OF RESPONDENTS**

---

JULIE SIMON MILLER  
MICHAEL S. SPECTOR  
AMERICA'S HEALTH  
INSURANCE PLANS  
601 Pennsylvania Ave., NW  
Washington, DC 20004

ANNA-ROSE MATHIESON  
*Counsel of Record*  
BEN FEUER  
CALIFORNIA APPELLATE  
LAW GROUP LLP  
96 Jessie Street  
San Francisco, CA 94105  
(415) 649-6700  
annarose@calapplaw.com

---

## TABLE OF CONTENTS

	Page
INTEREST OF AMICUS CURIAE.....	1
SUMMARY OF ARGUMENT.....	3
ARGUMENT .....	6
I. Congress Designed Inter Partes Review to Correct Inappropriate Patent Monopolies, Which (Among Other Harms) Drive up Drug Prices .....	6
A. Patents on prescription drugs significantly and directly affect health plan premiums and consumer costs .....	7
B. Patent monopolies reflect a policy judgment that higher costs are worthwhile for a short time, after which consumers will benefit from less costly alternatives.....	10
C. Congress designed inter partes review to reexamine inappropriately issued patents quickly and cost-effectively.....	13
II. Inter Partes Review Successfully Reex- amines Improper Patents .....	17
A. Inter partes review yields reasonable, appropriate results.....	17
B. Results for biopharmaceutical inter partes review generally track district court results for patent cases .....	20

**TABLE OF CONTENTS**  
(continued)

	<b>Page</b>
III. Eliminating Inter Partes Review Will Spur Patent Abuse and Harm Consumers.....	22
A. Inter partes review takes significantly less time and money than district court litigation .....	22
B. Eliminating inter partes review would reward patent abuse .....	26
C. Improper patents can stifle competition and deter innovation.....	30
CONCLUSION.....	32

## TABLE OF AUTHORITIES

	Page
<b>CASES</b>	
<i>Cuozzo Speed Techs., LLC v. Lee</i> 136 S. Ct. 2131 (2016).....	14, 19
<i>Dynamic Drinkware, LLC v. Nat’l Graphics, Inc.</i> 800 F.3d 1375 (Fed. Cir. 2015) .....	16
<i>Precision Instrument Mfg. Co. v. Auto. Maint. Mach. Co.</i> 324 U.S. 806 (1945).....	14
<i>Scott Paper Co. v. Marcalus Mfg. Co.</i> 326 U.S. 249 (1945).....	11, 30
<b>STATUTES, REGULATIONS &amp; LEGISLATIVE MATERIALS</b>	
157 Cong. Rec. 9778 (2011) .....	14
37 C.F.R. § 1.291 .....	16
37 C.F.R. § 42.107 .....	25
35 U.S.C. §§ 100 et seq.....	14
35 U.S.C. § 122 .....	16
35 U.S.C. § 132 .....	16
35 U.S.C. § 141 .....	16, 19
35 U.S.C. § 145 .....	16
35 U.S.C. § 314 .....	17, 25
35 U.S.C. § 316 .....	16, 25
35 U.S.C. § 319 .....	19
H.R. Rep. No. 112-98 (2011) .....	14
S. Rep. No. 110-259 (2008) .....	14

**TABLE OF AUTHORITIES**  
**(continued)**

	<b>Page</b>
 <b>OTHER AUTHORITIES</b>	
AHIP, <i>Where Does Your Premium Dollar Go?</i> (March 2, 2017), <a href="https://www.ahip.org/hhealth-care-dollar/">https://www.ahip.org/hhealth-care-dollar/</a> .....	8, 9
American Intellectual Property Law Association, <i>2015 Report of the Economic Survey</i> (June 2015) .....	23, 24
American Intellectual Property Law Association, <i>2017 Report of the Economic Survey</i> (June 2017) .....	3, 23, 24
Corinne E. Atton & April M. Breyer, Biologics/HQ Fitzgerald, <i>Drug Patents May Fare Better Than Other Technologies In IPR Proceedings</i> (June 12, 2017), <a href="http://www.biologicsshq.com/wp-content/uploads/2017/06/Drug-Patents-May-Fare-Better-Than-Other-Technologies-In-IPR-Proceedings.pdf">http://www.biologicsshq.com/wp-content/uploads/2017/06/Drug-Patents-May-Fare-Better-Than-Other-Technologies-In-IPR-Proceedings.pdf</a> .....	21
Courtenay C. Brinckerhoff, <i>Coherus Challenges One AbbVie Humira Patent In Four PTAB Proceedings</i> , PharmaPatents (July 18, 2017), <a href="https://www.pharmapatentsblog.com/2017/07/18/coherus-challenges-abbvie-humira-patent-in-four-ptab-proceedings/">https://www.pharmapatentsblog.com/2017/07/18/coherus-challenges-abbvie-humira-patent-in-four-ptab-proceedings/</a> .....	29
Amy Brown, Evaluate Grp., <i>EP Vantage 2017 Preview</i> (Dec. 2016), available at <a href="http://info.evaluategroup.com/rs/607-YGS-364/images/EPV2017Prev.pdf">info.evaluategroup.com/rs/607-YGS-364/images/EPV2017Prev.pdf</a> .....	27

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.